Amine Benmassaoud and Marc Bilodeau

and Learning Objectives

• Metabolic Management: The Endocrinology Perspective on SLD with Vanessa Tardio
  1. Review the current state of the obesity epidemic and its relationship to metabolic dysfunction associated steatotic liver disease (MASLD).
  2. Discuss the role of inflammation in obesity and its contribution to the pathogenesis and progression of fatty liver disease and related metabolic comorbidities.
  3. Examine current pharmacological treatment options for obesity, MASLD, and associated comorbidities, including therapies outlined in the Obesity Canada Pharmacotherapy Guidelines.
      
• Pathways for management Hepatology with Alnoor Ramji
  1. Review the FDA strategy for evaluation and approval for MASH drugs.
  2. Discuss MASH agents by MOA Review agents in mid and late stages of development and effect on MASH resolution and / or fibrosis.
  3. Review context of precision medicine in MASH.
  4. Consider the potential for combination of agents in the treatment of MASH.
      
• Frontline SLD Care: The Role of Primary Care with James Kim
  1. Discuss how primary care can be operationalized as a frontline setting for risk stratification and cardiometabolic co-management of MASLD, and recognize the supports.
  2. Identify strategies to strengthen referral pathways and shared-care models between primary care and hepatology.
      
• Cardiovascular risk assessment in patients with MASLD with George Thanassoulis
  1. How to evaluate cardiovascular risk in 2026;
  2. Should I measure apoB and Lp(a) in my patients?;
  3. What current CV risk reduction strategies should I implement with my patients?
      
• What’s Coming Next? Inside the MASH Pipeline with Mark Swain
  1. Understand the rapidly evolving landscape for MASH therapeutics.
  2. Defining liver, metabolic and alcohol intake-related therapeutic targets for intervention in MASH.